GLP-1 Weight Loss Drugs After 50: What to Know

GLP-1 drugs mimic a gut hormone to blunt appetite. Four now dominate weight-loss prescribing in the United States: Wegovy and Zepbound as injections, plus two pills, oral Wegovy and Foundayo. Medicare covers all four at a flat $50 per fill — Zepbound only as the KwikPen — through a temporary pilot that expires at the end of 2027. The open question for an older body is muscle.

This page lays out what GLP-1 weight loss actually involves after 50: what is approved, what it costs on Medicare, what the trials measured, and what to ask a clinician. It does not tell you whether to take one — that decision belongs to you and the person who writes your prescriptions. We are a research desk, not a clinic, and we did not examine anyone. This landscape changed twice in the last twelve months, so every figure below carries its source and its date.

If you want the version of this problem that does not involve a prescription, start with our guide to losing weight after 50.

The four drugs in the weight-loss conversation, and what they are actually called

Two are injections, two are pills:

• Wegovy (semaglutide), injection — the original weekly semaglutide approval for weight management.
• Zepbound (tirzepatide), injection — the weekly tirzepatide approval. Note the device: the Medicare pilot below covers the KwikPen only.
• Oral Wegovy (semaglutide 25 mg tablet) — approved December 22, 2025. Novo Nordisk's announcement calls it the first oral GLP-1 approved in the US for weight management, and Healio reported the same framing.
• Foundayo (orforglipron) — Eli Lilly's once-daily pill, approved April 1, 2026 for adults with obesity, or overweight plus at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity, according to Healio's report of the approval. It is the one with no food or water timing rules, which matters to anyone already juggling morning pills.

The FDA cleared Foundayo under its Commissioner's National Priority Voucher pilot, and the agency's own announcement called it the fastest approval of a new molecular entity since 2002.

One older drug belongs in the picture for completeness: Saxenda (liraglutide), a daily GLP-1 injection whose FDA label has carried a weight-management indication since 2014 and still does. It has been displaced by the newer drugs, and CMS does not list it among the drugs the Medicare pilot covers.

Ozempic and Mounjaro are the diabetes brands, not the weight-loss approvals

Ozempic and Wegovy are the same molecule, semaglutide. Mounjaro and Zepbound are the same molecule, tirzepatide. What differs is the approval each brand carries: Ozempic and Mounjaro are approved for type 2 diabetes, Wegovy and Zepbound for weight management. That is why the latter two are the ones in the obesity trials and the Medicare pilot.

So if a friend tells you Medicare now covers Ozempic for weight loss, that is not what happened. And if you already take a GLP-1 for diabetes, KFF Health News reports that you stay in your regular Part D plan and pay its price, which may be well above $50.

How much weight people lost in the trials, and why that is not a promise

For Foundayo, the approval rested on the ATTAIN program. In the 72-week, randomized, placebo-controlled ATTAIN-1 trial, Consultant360's report of the approval gives a mean reduction of 27.3 lb, or 12.4 percent, among participants on the highest dose who stayed on treatment, versus 2.2 lb (0.9 percent) on placebo. Counting everyone regardless of adherence, it was 25 lb (11.1 percent) versus 5.3 lb (2.1 percent).

For the Wegovy pill, the pivotal trial was OASIS 4, a trial in 307 adults that measured weight change at week 64. Healio's report puts average weight loss at 16.6 percent versus 2.7 percent on placebo when the analysis assumes continued adherence. The trial's own publication in the New England Journal of Medicine in 2025 reports 13.6 percent versus 2.2 percent counting everyone as randomized. One in three participants lost 20 percent or more of body weight, Healio reports.

Two things matter more than the numbers:

• The high and low figure answer different questions. The higher assumes you keep taking the drug as directed; the lower counts everybody who enrolled, including people who stopped. Marketing quotes the first.
• These trials were not run in people your age. They enrolled adults with obesity. The spread inside those averages is enormous, and none of these figures estimates what a 68-year-old will experience.

If you want the mechanism behind the plateau first, we covered why the weight stopped coming off separately.

Medicare's GLP-1 Bridge: $50 a fill, through December 2027

The verified core, per KFF Health News and plan communications:

• It is a pilot, not a benefit. The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 — extended to 18 months, KFF reports, after CMS originally planned six.
• The copay is a flat $50 per fill, and it does not climb as your dose climbs.
• It covers Wegovy (injection and pill), the Zepbound KwikPen, and Foundayo.
• Prior authorization is required. Highmark's provider communication describes prescribers sending the request to a central processor that handles authorization, claims and pharmacy payment. CMS's own prescriber document adds that once the first fill is approved, later fills need no new authorization unless the patient switches to a different covered GLP-1, and that only 28-day or 30-day fills are covered.
• There is no separate enrollment. You need a Part D plan, but the Bridge works outside it and the pharmacy processes the claim.
• Eligibility turns on BMI plus clinical criteria, and the prescriber attests that you met them. CMS's prescriber document, "Medicare GLP-1 Bridge: Information for Prescribers," lists the clinical criteria as a BMI of at least 35; or a BMI of at least 30 plus heart failure with preserved ejection fraction, uncontrolled hypertension despite two blood-pressure medications, or chronic kidney disease stage 3a or above; or a BMI of at least 27 plus prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease. CMS reads BMI as of the time GLP-1 therapy starts rather than the day of the request, and the Bridge is only for people not already eligible for a GLP-1 through their own Part D plan and without type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. Secondhand summaries of those tiers often garble them, so confirm your own case against the CMS document or your Part D plan rather than a news write-up.

KFF put the scale of that in context: analysing 2023 data, it found nearly four million Medicare beneficiaries would have met the Bridge eligibility criteria.

What the $50 does not do

• It does not count toward your Part D deductible, because the Bridge sits outside Part D.
• It does not count toward the annual out-of-pocket cap, which KFF Health News puts at $2,100.
• Extra Help does not reduce it. KFF reports that low-income subsidy recipients cannot apply that assistance to Bridge drugs, so the $50 is the $50.
• It is not nothing. KFF quotes Juliette Cubanski of KFF's Program on Medicare Policy: $50 a month "sounds like a great deal compared to paying the discounted prices through TrumpRx," but "it's a lot of money for somebody who's living on a $750-a-month Social Security check."

The expiration date is the real planning problem

December 31, 2027 is not far away, and what follows is unknown. KFF Health News reports that a longer-term program shifting these costs to insurers might begin in 2028, or might not, because insurers did not sign up in sufficient numbers by the April deadline.

One more coverage note: compounded GLP-1 products are not what the Bridge covers. The FDA issued an alert in July 2024 about dosing errors with compounded injectable semaglutide, including reports of people administering many times the intended dose, and its position as described in that coverage is that it does not review compounded versions for safety, effectiveness or quality.

The muscle question, and the number everyone gets wrong

The best primary data come from the exploratory body-composition analysis published alongside the STEP 1 semaglutide trial in the New England Journal of Medicine in 2021. In its DXA subpopulation, at week 68:

• Fat mass fell 8.36 kg on semaglutide, versus 1.37 kg on placebo.
• Total lean body mass fell 5.26 kg on semaglutide, versus 1.83 kg on placebo.
• That lean loss was 9.7 percent of baseline lean mass — the figure the same investigators reported when they presented the substudy at the Endocrine Society's ENDO 2021 meeting — and in the NEJM appendix table, the proportion of lean mass relative to total body mass rose by 3.0 percentage points.

Both halves of that last line are true at once. Lean mass fell in absolute terms while making up more of the body than before, because fat fell faster. Do the arithmetic on those kilograms and roughly 38 percent of the weight lost was lean mass. The 45 percent figure that circulates widely does not reconcile with them, and the "10 to 15 percent muscle loss" line clinic blogs repeat has no primary source we could find.

Two caveats are mandatory. The DXA group was 140 participants, body composition was a supportive secondary endpoint, and the subpopulation was limited by BMI. And DXA "lean mass" includes water and organ tissue, not just muscle — 9.7 percent of lean mass is not a tenth of your muscle.

How much of it is muscle is still contested. Endocrine News, reporting on an Annals of Internal Medicine editorial by Anjali P. Kakkar and colleagues titled "Skeletal Muscle Mass Loss and Glucagon-Like Peptide-1 Receptor Agonists: Are Older Patients at Risk?", cites a 2024 review in Diabetes, Obesity and Metabolism finding that 15 to 60 percent of weight lost on these drugs may come from lean mass, depending on the patient and the drug. A range that wide is a statement about the evidence, not about your body. The editorial's own view is that these drugs "may exacerbate sarcopenia" and that adults over 65 are "particularly vulnerable."

Age changes the stakes. A 2025 review in Frontiers in Aging by Kieran Reid and Shalender Bhasin, "Moving beyond the scale," notes that loss of skeletal muscle mass is a critical determinant of ambulation and physical function in older adults. At 35 that loss is cosmetic; at 70 it can cost a staircase. We go through this in depth, drugs aside, in how to keep muscle while losing weight.

What the evidence says about protecting muscle

A 2026 scoping review in Current Nutrition Reports by Simsek and Uçar, "GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity," concludes that pairing GLP-1 therapy with tailored resistance exercise and dietary counseling including 1.2 to 1.6 g/kg/day of protein may help preserve muscle mass and function in older adults. The same review states plainly that data on muscle mass and physical performance remain limited and inconsistent. Carry that limitation with the recommendation. The Annals editorial reported by Endocrine News lands in the same place, and notes that no drugs are approved to prevent muscle loss — which is why food and exercise are the only levers available.

The strongest trial evidence that exercise changes the composition of weight loss involves no drugs at all. In Villareal and colleagues' 2017 New England Journal of Medicine trial, 160 obese older adults were randomized to a six-month weight-management program plus aerobic, resistance or combined exercise, or to a control group that got neither. Lean mass fell least with resistance training, down 1.0 kg (2 percent), versus 1.7 kg (3 percent) for aerobic plus resistance and 2.7 kg (5 percent) for aerobic alone. The part that gets flattened is the part that matters: the combination group had the greatest improvement in physical function, and the trial favours doing both.

On protein, be careful whose number you are quoting. The 2025-2030 Dietary Guidelines for Americans list protein serving goals of 1.2 to 1.6 grams per kilogram of body weight per day, adjusted to individual calorie needs — but the Dietary Guidelines do not set Dietary Reference Intakes, and the adult RDA from the National Academies remains 0.8 g/kg/day. Both are true, and they answer different questions. The higher range is also contested among nutrition scientists rather than settled. We work through that in how much protein you need after 50, and our protein calculator does the arithmetic on your own weight.

One exception is not optional: if you have reduced kidney function, these targets are not yours. Protein targets in chronic kidney disease are individualized by stage — a conversation for your clinician, not a calculator.

The barrier to strength work after 50 is usually logistics, not load, which is why we reviewed resistance bands.

Side effects, written for an older body

The common adverse events are gastrointestinal. Consultant360's report on Foundayo lists nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain, and Healio reports the same pattern for the Wegovy pill, with nausea, vomiting and constipation most common.

The labels carry specific warnings worth reading rather than summarizing. The FDA-hosted prescribing information for Wegovy lists acute pancreatitis, with instructions to discontinue if pancreatitis is suspected; acute gallbladder disease, with gallbladder studies indicated if cholelithiasis is suspected; acute kidney injury due to volume depletion, with renal function monitored in patients reporting reactions that could cause it; and severe gastrointestinal reactions, with the drug not recommended in severe gastroparesis. Foundayo's FDA prescribing information carries a boxed warning for thyroid C-cell tumors, and the label contraindicates the drug in people with a personal or family history of medullary thyroid cancer or with multiple endocrine neoplasia syndrome type 2.

Constipation is the side effect most often managed badly. Fiber is the usual first move, and the type matters more than the label on the tub — we sorted that evidence in best fiber supplements. Fiber supplements need plenty of water and can interfere with absorption of some medications, so run the timing past a pharmacist if your prescription list is long.

The dehydration pathway is the genuinely age-specific risk

These drugs reduce appetite, and patient guidance from health systems reports they can blunt thirst along with it. Guthrie's patient guidance for older adults on GLP-1s makes the compounding problem explicit: "Older adults are already more likely to become dehydrated because their sense of thirst becomes weaker with age." Add a drug that quiets both signals to a body whose thirst signal was already quiet, and someone can eat and drink far less than they need without ever feeling it. Guthrie lists dark urine, dizziness and dry mouth among the warning signs, and notes that because the medications reduce appetite, "you may eat much less," leaving you short of the nutrients needed to maintain muscle.

Follow the chain. Reduced intake tips toward undernutrition and dehydration. Dehydration is the volume-depletion pathway the Wegovy label flags for acute kidney injury. Undernutrition accelerates the lean-mass loss above. And Guthrie's guidance notes that muscle loss makes daily tasks harder and increases the risk of falls. None of that is inevitable, and all of it is monitorable — which is the argument for a plan before the first dose, not after a bad week.

For a baseline, we laid out the health numbers worth tracking after 50. The most useful thing to record first is a measure of function, not a number on a scale.

What happens when you stop

Anyone considering a drug under a pilot that expires in December 2027 needs this before the first prescription.

STEP 1 included a one-year off-treatment extension, published by Wilding and colleagues in Diabetes, Obesity and Metabolism in 2022. Participants had lost roughly 17 percent of body weight over 68 weeks on semaglutide. By week 120, a year after stopping, the semaglutide group had regained 11.6 percentage points of the weight they had lost, versus 1.9 in the placebo group, leaving net losses of 5.6 percent and 0.1 percent. Cardiometabolic improvements reverted toward baseline for most measures. The authors conclude that the findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain the improvement. Those extension analyses were exploratory and the trial was manufacturer-funded. KFF Health News notes the same regain pattern in its Bridge reporting.

The mismatch is structural, not personal: a time-limited coverage program and a chronic condition fit badly together, and that is worth raising before starting rather than discovering in 2028.

Where the evidence is genuinely thin

We looked for a formal 2026 clinical guideline from a major society on GLP-1 use in adults 65 and over, and did not find one. That absence is the honest headline here. What exists instead is an editorial, a scoping review, extrapolation from the wider sarcopenia literature, and — published in the Journal of the American Geriatrics Society on October 29, 2026, days before this page — an American Geriatrics Society expert framework, not a guideline, which asks clinicians to weigh function, nutrition and cognition before starting an incretin drug in an older adult and names resistance training and adequate protein as the co-interventions.

• Frailty and sarcopenic obesity in this age group are open questions. The 2026 Current Nutrition Reports review calls for more work on muscle quantity, quality and function for that reason.
• Head-to-head lean-mass comparisons between drugs are not settled. The most-cited direct comparison we found is a real-world cohort circulating as a preprint, not peer reviewed, so we are not repeating its numbers.
• Figures that look authoritative online often are not. Claims about lean loss over 65 or 70 with one drug versus another conflict with each other and trace to no primary source we could find.

Questions worth taking to your clinician

• How will we monitor muscle and function, not just weight? Ask what gets measured at baseline — grip strength, chair-stand time, walking speed — and when it is measured again.
• What is the plan when coverage ends? The Bridge expires December 31, 2027.
• What is the plan for regain? Given the STEP 1 extension findings, ask before starting.
• How does this interact with everything else I take? These drugs slow gastric emptying, which can change how other medications are absorbed. Bring the full list.
• What should I be eating, and how much protein? Ask for a target in your own numbers, and say so if you have reduced kidney function.
• What strength work, starting when? The evidence puts this in the plan from the start, not as a rescue after function drops.
• At what point would we stop? Ask what a bad outcome looks like and what the threshold for stopping is.

What to do with this

We are not going to tell you whether to take a GLP-1. We do not know your weight history, your kidney function, or what the last twenty years of trying have cost you, and anyone online who will make that call for you is not being straight with you.

Three things are worth doing either way. Gather your numbers — weight, waist, a baseline measure of strength or function, and your kidney function if you do not know it. Take the question list above to an appointment, and confirm coverage with your own Part D plan rather than a blog, this one included. And do the resistance training and eat the protein regardless, because the evidence we found, thin as parts of it are, points consistently in one direction: the drug does most of the work on how much weight comes off, and what you do with your body and your plate appears to shape how much of it is muscle.

For the non-pharmacological version of all of this, built for the same reader, see our complete guide to weight loss after 50.